



## **Ocular Therapeutix™ to Present at the 17th Annual BIO CEO & Investor Conference**

February 4, 2015

BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 4, 2015-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Brad Smith, Chief Financial Officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:30 p.m. Eastern Time at the Waldorf Astoria in New York City.

A live webcast will be accessible through Ocular's website at [www.ocutx.com](http://www.ocutx.com) in the Investors section under Calendar of Events. A replay of the presentation will also be available.

### **About Ocular Therapeutix, Inc.**

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, allergic conjunctivitis, and dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

### **Investors:**

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

[bsmith@ocutx.com](mailto:bsmith@ocutx.com)

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

[kminarovich@burnsmc.com](mailto:kminarovich@burnsmc.com)

or

### **Media:**

Ocular Therapeutix, Inc.

Scott Corning

Vice President of Sales and Marketing

[scorning@ocutx.com](mailto:scorning@ocutx.com)